These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 15464445)

  • 41. Genotype-phenotype relationship for five CFTR mutations frequently identified in western France.
    Duguépéroux I; De Braekeleer M;
    J Cyst Fibros; 2004 Dec; 3(4):259-63. PubMed ID: 15698945
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mouse models of cystic fibrosis: phenotypic analysis and research applications.
    Wilke M; Buijs-Offerman RM; Aarbiou J; Colledge WH; Sheppard DN; Touqui L; Bot A; Jorna H; de Jonge HR; Scholte BJ
    J Cyst Fibros; 2011 Jun; 10 Suppl 2():S152-71. PubMed ID: 21658634
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Cystic fibrosis modifying genes].
    Knauer N; Ratjen F; Grasemann H
    Pneumologie; 2005 Jun; 59(6):395-404. PubMed ID: 15991075
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sendai virus-mediated CFTR gene transfer to the airway epithelium.
    Ferrari S; Griesenbach U; Iida A; Farley R; Wright AM; Zhu J; Munkonge FM; Smith SN; You J; Ban H; Inoue M; Chan M; Singh C; Verdon B; Argent BE; Wainwright B; Jeffery PK; Geddes DM; Porteous DJ; Hyde SC; Gray MA; Hasegawa M; Alton EW
    Gene Ther; 2007 Oct; 14(19):1371-9. PubMed ID: 17597790
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gene therapy for cystic fibrosis.
    Davies JC; Geddes DM; Alton EW
    J Gene Med; 2001; 3(5):409-17. PubMed ID: 11601754
    [TBL] [Abstract][Full Text] [Related]  

  • 46. What happens to deltaF508 in vivo?
    Drumm M
    J Clin Invest; 1999 May; 103(10):1369-70. PubMed ID: 10330418
    [No Abstract]   [Full Text] [Related]  

  • 47. [Cystic fibrosis: a complex disease and a paradigm for biomedical research].
    Tirouvanziam R
    J Soc Biol; 1999; 193(2):189-209. PubMed ID: 10451354
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Curcumin and genistein: the combined effects on disease-associated CFTR mutants and their clinical implications.
    Sohma Y; Yu YC; Hwang TC
    Curr Pharm Des; 2013; 19(19):3521-8. PubMed ID: 23331029
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Revisiting the mouse lung model for CF.
    Boyd AC; Porteous DJ
    Gene Ther; 2004 May; 11(9):737-8. PubMed ID: 14999230
    [No Abstract]   [Full Text] [Related]  

  • 50. Gene therapy for cystic fibrosis: challenges and future directions.
    Wilson JM
    J Clin Invest; 1995 Dec; 96(6):2547-54. PubMed ID: 8675618
    [No Abstract]   [Full Text] [Related]  

  • 51. Hepatic iodothyronine deiodinase type 1 activity is decreased in two DeltaF508 cystic fibrosis mouse models.
    Klaren PH; Looijmans PH
    J Cyst Fibros; 2004 Jun; 3(2):125-8. PubMed ID: 15463895
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cystic fibrosis: CFTR modulators and their mechanism of action.
    Nieddu E
    Curr Pharm Des; 2013; 19(19):3474-5. PubMed ID: 23331031
    [No Abstract]   [Full Text] [Related]  

  • 53. Cystic fibrosis-related bone disease.
    Paccou J; Fardellone P; Cortet B
    Curr Opin Pulm Med; 2013 Nov; 19(6):681-6. PubMed ID: 24060979
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Detergent-lentiviral combination gives gene therapy hope for cystic fibrosis.
    Bradbury J
    Lancet; 2002 Oct; 360(9342):1306. PubMed ID: 12414210
    [No Abstract]   [Full Text] [Related]  

  • 55. A Link Between a Common Mutation in CFTR and Impaired Innate and Adaptive Viral Defense.
    Svedin E; Utorova R; Hühn MH; Larsson PG; Stone VM; Garimella M; Lind K; Hägglöf T; Pincikova T; Laitinen OH; McInerney GM; Scholte B; Hjelte L; Karlsson MCI; Flodström-Tullberg M
    J Infect Dis; 2017 Dec; 216(10):1308-1317. PubMed ID: 28968805
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Curcumin/poly(2-methyl-2-oxazoline-b-tetrahydrofuran-b-2-methyl-2-oxazoline) formulation: An improved penetration and biological effect of curcumin in F508del-CFTR cell lines.
    Gonçalves C; Gomez JP; Même W; Rasolonjatovo B; Gosset D; Nedellec S; Hulin P; Huin C; Le Gall T; Montier T; Lehn P; Pichon C; Guégan P; Cheradame H; Midoux P
    Eur J Pharm Biopharm; 2017 Aug; 117():168-181. PubMed ID: 28427956
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cystic fibrosis, a multi-systemic mucosal disease: 25 years after the discovery of CFTR.
    Edelman A; Sallenave JM
    Int J Biochem Cell Biol; 2014 Jul; 52():2-4. PubMed ID: 24735713
    [No Abstract]   [Full Text] [Related]  

  • 58. The spice of life for cystic fibrosis.
    Croft NM
    Gastroenterology; 2004 Nov; 127(5):1639-40. PubMed ID: 15521034
    [No Abstract]   [Full Text] [Related]  

  • 59. [New therapeutic modalities for pulmonary disease in cystic fibrosis].
    Virgilis D; Augarten A; Szeinberg A; Yahav Y
    Harefuah; 1995 Dec; 129(12):569-72. PubMed ID: 8682360
    [No Abstract]   [Full Text] [Related]  

  • 60. The prevalence of DeltaF508 in primary osteoporotic patients.
    Treszl A; Németh K; Kocsis I; Vásárhelyi B; Fekete G; Tulassay T; Szathmári M
    Eur Respir J; 2005 Aug; 26(2):362-3. PubMed ID: 16055889
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.